Intuitive Surgical beats Q3 estimates but shares fall on pricing
Representative image: sasint / Pixabay
Intuitive Surgical's Q3 2026 revenue rose 22% to $3.05 billion, beating estimates, but its shares fell after hours on October 20 over instrument price cuts.
What Happened
Shares of Intuitive Surgical, the maker of the da Vinci surgical robot, fell sharply in after-hours trading on Tuesday, October 20, 2026, even though its third-quarter results beat Wall Street estimates. The company reported revenue of $3.05 billion, up about 22% from a year earlier, and adjusted earnings of $3.00 a share, according to its earnings release. Investors focused instead on planned price cuts for the instruments used in each operation and on a $450 million litigation settlement charge, according to market reports.
Key Facts
- Revenue: $3.05 billion for July to September 2026, up about 22% year on year, against analysts' estimates of about $2.91 billion.
- Earnings: adjusted earnings of $3.00 a share against estimates of about $2.64; reported (GAAP) earnings of $1.49 a share, reduced by a $450 million pre-tax litigation settlement charge.
- Procedures: worldwide procedures using its da Vinci and Ion systems grew about 15%; da Vinci procedures rose about 14% and Ion procedures about 31%.
- Placements: 546 da Vinci systems placed in the quarter, up from 427 a year earlier.
- Installed base: 12,094 da Vinci systems as of September 30, 2026, up 12%.
- Pricing: the company expects instrument and accessory pricing actions to reduce da Vinci instrument revenue per procedure by about 3% to 5% on a mix-constant basis, according to reports of its guidance.
- Outlook: full-year 2026 da Vinci procedure growth of about 14% to 15%, and a gross margin of 68.7% to 69.3%.
Why It Matters
Intuitive Surgical sells robotic systems that surgeons control from a console to perform minimally invasive operations through small incisions. Its business has two parts: selling or leasing the robots, and selling the instruments and accessories that are used, and replaced, in every procedure. The second part provides steady, recurring revenue that grows as more operations are done.
That is why the market reacted to pricing rather than to the headline beat. A planned 3% to 5% cut in instrument revenue per procedure, if it happens, would reduce income from the most reliable part of the business, even if the number of procedures keeps rising. Investors who pay a high price for a company's shares often focus on the future margin outlook more than on a single quarter's profit.
The underlying demand numbers were strong. Procedure growth of about 15% and a 28% jump in system placements, from 427 to 546, show hospitals continuing to buy and use the robots. Procedures on its Ion system grew fastest, at about 31%. The $450 million settlement charge is a one-off cost that lowered reported earnings but not the adjusted figure that analysts use to judge performance.
For investors in India who hold US healthcare or technology shares, the results are another example this week of a company beating estimates but falling on its outlook. This is not investment advice.
| Measure | Q3 2026 |
|---|---|
| Revenue | $3.05 billion (up about 22%) |
| Adjusted EPS | $3.00 |
| Reported EPS | $1.49 |
| da Vinci systems placed | 546 (427 a year earlier) |
| Worldwide procedure growth | About 15% |
Impact
Short-term: The after-hours fall points to pressure on the shares when regular trading opens on October 21, though the size of the move was not confirmed in reports. Analysts will look for detail on the pricing changes.
Long-term: Strong procedure growth supports the business, but lower instrument prices could slow revenue per operation. How hospitals respond to lower prices, and whether it lifts volumes further, will shape future results.
Who is affected: Intuitive Surgical shareholders, hospitals that use da Vinci and Ion systems, surgeons trained on the robots, and patients undergoing robotic-assisted surgery.
Key Takeaway
Intuitive Surgical beat third-quarter estimates on October 20, 2026 with revenue of $3.05 billion, but its shares fell after hours as investors focused on planned instrument price cuts and a $450 million settlement charge.
Questions and Answers
Why did ISRG stock fall after Q3 2026 earnings?
Intuitive Surgical's shares fell after hours on October 20, 2026 despite beating estimates, as investors focused on planned instrument pricing actions expected to cut revenue per procedure by about 3% to 5%, and on a $450 million litigation charge.
What were Intuitive Surgical's Q3 2026 results?
Revenue was $3.05 billion, up about 22%, with adjusted earnings of $3.00 a share and reported earnings of $1.49 a share.
How many da Vinci systems did Intuitive place in Q3 2026?
The company placed 546 da Vinci systems, up from 427 a year earlier, and its installed base reached 12,094 systems.
What is Intuitive Surgical's 2026 outlook?
It expects da Vinci procedures to grow about 14% to 15% in 2026 and a gross margin of 68.7% to 69.3% of revenue.
Disclaimer: Prepared by the Peepals newsroom from publicly available sources with AI assistance. Information is accurate to the best of our knowledge at the time of publication and may change. Images may be representative. Not professional advice. Report an error via our contact page.
Sourced and fact-checked by the Peepals Global Editorial Team
Supermicro raises quarterly revenue estimate by $4 billion on AI demand
PHP critical flaws: emergency patch due today, older servers left exposed
Reported, fact-checked and published by the Peepals Global Editorial Team.
